Eximis Surgical
- Industry
- Medical Devices & Equipment
- Founded Year
- 2014
- Headquarters
- 315 W South Boulder Rd Ste 110, Louisville, Colorado, 80027, United States
- Employee Count
- 18
Key People
- Donna Ford-Serbu - CEO and Co-Founder
- Kristin Johnson - Co-Founder
- William Gregg - Co-Founder and Director of R&D
- Bob Luzzi - VP of R&D
- Ryan Smith - Director of R&D
- Chris Underwood - Director of Operations
- Steven Choi - Principal Mechanical Engineer
- Gabriel Chapel - Mechanical Design Engineer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in medical devices.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's credibility and potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: The product addresses a significant need in minimally invasive surgery for efficient specimen removal.
The device's ability to remove large specimens through small incisions meets a critical need in minimally invasive procedures, potentially improving patient outcomes and surgical efficiency.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has existing solutions, but Eximis Surgical offers a unique approach.
While there are existing products for specimen removal in minimally invasive surgery, Eximis Surgical's technology offers a novel method that could provide competitive advantages.
- Technical Challenge
-
Aspect: Moderate
Summary: The technology involves controlled RF energy, presenting moderate technical challenges.
Developing a device that safely and effectively uses RF energy for tissue segmentation requires careful engineering and validation to ensure safety and efficacy.
- Patent
-
Aspect: Strong
Summary: The company holds patents for its tissue removal system and methods.
Patents such as US9649147 and US9522034 provide intellectual property protection, potentially preventing competitors from replicating the technology.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
With funding rounds totaling at least $7.5 million from investors like Questa Capital and Olympus Innovation Ventures, the company is well-positioned financially to advance its product development and market entry.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The company is in the pre-market phase, working towards FDA submission.
As the company is actively working towards FDA submission, obtaining regulatory approval will be essential for market entry and success.
Opportunity Rollup
- Odds of Success
- 4.05
- Peak Market Share
- 5.7
- Segment CAGR
- 4.0%
- Market Segment
- General Surgery Devices
- Market Sub Segment
- Minimally Invasive Surgical Instruments
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.29 |
| 2 | 0.86 |
| 3 | 2.00 |
| 4 | 3.99 |
| 5 | 5.70 |
Key Takeaway
Eximis Surgical's innovative technology addresses a significant clinical need in minimally invasive surgery, supported by a strong team and solid funding, but faces challenges in a competitive market and regulatory approval process.